Latest Healthcare Sector News

Epsilon Healthcare and its subsidiaries have officially exited voluntary administration and Deeds of Company Arrangement, marking a pivotal recovery milestone supported by significant personal commitments from the new board. The company now shifts focus to strategic growth and rebuilding trust.

ParagonCare appoints Carmen Riley as CEO effective July 1, 2025, with a planned transition period under outgoing CEO David Collins to complete integration and pursue M&A opportunities.

BlinkLab Limited has responded to an ASX query regarding recent unusual trading activity, confirming no undisclosed material information exists and highlighting pending ADHD diagnostic results expected later this year.

Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.

Universal Biosensors has requested a voluntary suspension of its shares on the ASX, pending details of a proposed capital raising. The suspension is expected to last until the end of June or until the announcement is made.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

Arena REIT has declared a quarterly distribution of 4.5625 cents per security, consistent with its FY25 guidance, while offering a 1.5% discount on reinvested dividends through its DRP.

Vita Life Sciences projects solid revenue growth of up to 16% for the first half of 2025, driven by strong performance in Australia, Malaysia, and Singapore, even as sales in China dip below last year’s levels.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Monash IVF Group has announced the resignation of CEO Michael Knaap, with CFO Malik Jainudeen stepping in as Acting CEO during the leadership transition.

Cochlear Limited has lowered its FY25 earnings guidance due to slower-than-expected sales growth and a sharper decline in Services revenue. Despite this, implant unit growth remains on track, driven by emerging markets.

Integral Diagnostics has announced the planned retirement of CEO Dr Ian Kadish at the end of FY26, with an international search underway for his successor. The transition comes as the company focuses on integrating its recent merger with Capitol Health.